Anglo-Swiss life sciences investment company Medicxi has raised $400 million for its fourth fund, which will focus on supporting ‘asset-centric’ companies at all stages of drug development.The Medicxi IV fund will concentrate on “drug hunters with clear product visions to deliver transformative therapies for patients,” said the firm in a statement.It is the latest in […]
